CO-VANTAGE-DATA-CENTERS
13.12.2022 14:01:34 CET | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, announced today the construction of a second campus (JNB2) in Johannesburg, South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005272/en/
JNB11 facility on Vantage Data Centers' developing 80MW campus in Johannesburg, South Africa. The company is now developing a second campus 17 kilometers away. (Photo: Business Wire)
The JNB2 Isando campus is strategically located in Ekurhuleni, the greater Johannesburg Metropol’s trade and industry hub, and approximately 17 kilometers from Vantage’s growing JNB1 Midrand campus. JNB2 is sited near the OR Tambo International Airport and less than two kilometers from the NAPAfrica neutral Internet eXchange in a region that serves as the cloud on-ramp for a number of large technology companies.
“South Africa continues to be a cornerstone for Vantage’s EMEA growth outside of continental Europe,” said Antoine Boniface, president, Vantage Data Centers, EMEA. “Investing in a second campus is a testament to our commitment to the region and our customers who have business requirements to be in this high-demand market.”
The first building of the JNB2 campus will consist of a 20MW 355,000 square foot (33,000 square meters) two-story data center and will be operational in mid-2024. Vantage is repurposing a portion of an existing warehouse for the initial phase, reducing the embodied carbon of the development.
Sustainable Design
Many features of JNB2 are based on Vantage’s standardized campus blueprint, emphasizing sustainable construction practices. This includes offering renewable energy options through a recent Power Purchase Agreement with SolarAfrica, limiting carbon footprints, maintaining energy efficient operations with an industry-leading power usage effectiveness (PUE) and minimizing the use of water.
Power and Cooling
The first data center on the JNB2 campus will be cooled using a highly efficient, closed-loop chilled water system generated through air-cooled chillers. An integrated economizer capability will allow reduced compressor energy based on outside ambient temperature. This allows Vantage to take advantage of cooler seasonal temperatures to minimize resource usage. Customers will benefit from power provided by the Municipality of Ekurhuleni, combined with a dedicated on-site, high-voltage substation.
Security and Amenities
Campus security remains a priority for Vantage, and the company’s hallmark security measures include an on-site security operations center with 24x7x365 patrols, perimeter security, CCTV on all access points, and multi-level authentication and access controls for employees, customers and visitors.
This new data center will provide dedicated offices and workspaces, break areas, conference rooms, meeting spaces and secure storage areas.
JNB1 Expansion
On Vantage’s inaugural and award-winning 80MW campus in Midrand, South Africa, the company opened its first 16MW facility in July 2022, and continues expanding the development to meet customer demand. The next phase is under construction and is slated to be operational in early 2024.
For more information about Vantage’s global campus footprint, visit https://vantage-dc.com/data-center-locations/.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
